{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T09:48:35Z","timestamp":1790416115469,"version":"4.1.0"},"reference-count":196,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100015330","name":"Max Kade Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.ahj.2024.01.004","type":"journal-article","created":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T22:45:14Z","timestamp":1705790714000},"page":"23-43","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Drug development for major chronic health conditions\u2014aligning with growing public health needs: Proceedings from a multistakeholder think tank"],"prefix":"10.1016","volume":"270","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7792-2837","authenticated-orcid":false,"given":"Konstantin A.","family":"Krychtiuk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas LG","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Bodesheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley H.","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Elkind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian F.","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Hornik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary H.","family":"Lyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Khatri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mbagwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwen","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lothar","family":"Roessig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Quinn","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L.","family":"Schilsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Pagidipati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2024.01.004_bib0001","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/d41573-022-00001-9","article-title":"2021 FDA approvals","volume":"21","author":"Mullard","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ahj.2024.01.004_bib0002","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/d41573-022-00015-3","article-title":"2021 FDA approvals: value driven by COVID-19 vaccines","volume":"21","author":"Baedeker","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ahj.2024.01.004_bib0003","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1016\/j.drudis.2022.04.010","article-title":"2021 in review: FDA approvals of new medicines","volume":"27","author":"Kinch","year":"2022","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.ahj.2024.01.004_bib0004","unstructured":"IQVIA: the global use of medicines 2022 - Outlook to 2026 - https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports\/the-global-use-of-medicines-2022 (accessed 12 February, 2022)."},{"key":"10.1016\/j.ahj.2024.01.004_bib0005","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1200\/JCO.2018.78.5592","article-title":"Evolving landscape of US Food and Drug Administration Drug approval in the era of precision oncology: finding the right balance between access and safety","volume":"36","author":"Kuderer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ahj.2024.01.004_bib0006","series-title":"NCHS Data Brief No 427 December 2021","article-title":"Mortality in the United States, 2020","author":"Murphy","year":"2021"},{"key":"10.1016\/j.ahj.2024.01.004_bib0007","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1161\/CIRCULATIONAHA.121.053461","article-title":"Avoiding the coming tsunami of common, chronic disease: what the lessons of the COVID-19 pandemic can teach us","volume":"143","author":"Califf","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2024.01.004_bib0008","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1001\/jama.2023.2307","article-title":"Cardiovascular risk factor prevalence, treatment, and control in US adults aged 20 to 44 years, 2009 to March 2020","volume":"329","author":"Aggarwal","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2024.01.004_bib0009","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jacc.2022.05.033","article-title":"Cardiovascular disease projections in the United States based on the 2020 census estimates","volume":"80","author":"Mohebi","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2024.01.004_bib0010","unstructured":"IQVIA EFPIA pipeline review 2021: full report https:\/\/www.efpia.eu\/media\/602563\/iqvia_efpia_pipeline-review_final.pdf accessed 11 October, 2022."},{"key":"10.1016\/j.ahj.2024.01.004_bib0011","unstructured":"Fierce Pharma: the top 20 drugs by worldwide sales in 2020 (https:\/\/www.fiercepharma.com\/special-report\/top-20-drugs-by-2020-sales - accessed September 24, 2023."},{"key":"10.1016\/j.ahj.2024.01.004_bib0012","unstructured":"IMS Institute for Healthcare Informatics: global medicines use in 2020: outlook and implications (https:\/\/www.iqvia.com\/-\/media\/iqvia\/pdfs\/institute-reports\/global-medicines-use-in-2020 accessed 24 September, 2023)."},{"key":"10.1016\/j.ahj.2024.01.004_bib0013","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.jacc.2015.03.016","article-title":"Cardiovascular drug development: is it dead or just hibernating?","volume":"65","author":"Fordyce","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2024.01.004_bib0014","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.120.006606","article-title":"Improving cardiovascular drug and device development and evidence through patient-centered research and clinical trials: a call to action from the value in healthcare initiative's partnering with regulators learning collaborative","volume":"13","author":"Warner","year":"2020","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.ahj.2024.01.004_bib0015","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ahj.2024.01.004_bib0016","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1158\/1535-7163.MCT-21-0950","article-title":"Tissue-agnostic activity of BRAF plus MEK inhibitor in BRAF V600-mutant tumors","volume":"21","author":"Adashek","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ahj.2024.01.004_bib0017","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1200\/JCO.2016.67.3160","article-title":"Biomarker tests for molecularly targeted therapies: laying the foundation and fulfilling the dream","volume":"34","author":"Lyman","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ahj.2024.01.004_bib0018","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1056\/NEJMp1604033","article-title":"Biomarker tests for molecularly targeted therapies: the key to unlocking precision medicine","volume":"375","author":"Lyman","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.01.004_bib0019","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1158\/2159-8290.CD-22-1185","article-title":"Highlights of FDA oncology approvals in 2022: tissue-agnostic indications, dosage optimization, and diversity in drug development","volume":"12","author":"Duke","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ahj.2024.01.004_bib0020","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13112758","article-title":"Drug development in tissue-agnostic indications","volume":"13","author":"du Rusquec","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ahj.2024.01.004_bib0021","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jamaoncol.2017.5618","article-title":"A 25-year experience of US Food and Drug Administration accelerated approval of malignant hematology and oncology drugs and biologics: a review","volume":"4","author":"Beaver","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ahj.2024.01.004_bib0022","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMra1510062","article-title":"Master protocols to study multiple therapies, multiple diseases, or both","volume":"377","author":"Woodcock","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.01.004_bib0023","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1001\/jama.2021.22507","article-title":"How to use and interpret the results of a platform trial: users' guide to the medical literature","volume":"327","author":"Park","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2024.01.004_bib0024","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1093\/eurheartj\/ehab236","article-title":"What can heart failure trialists learn from oncology trialists?","volume":"42","author":"Zannad","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2024.01.004_bib0025","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1158\/1078-0432.CCR-22-3334","article-title":"National Cancer Institute combination therapy platform trial with molecular analysis for therapy choice (ComboMATCH)","volume":"29","author":"Meric-Bernstam","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ahj.2024.01.004_bib0026","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1056\/NEJMra1510061","article-title":"Adaptive designs for clinical trials","volume":"375","author":"Bhatt","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.01.004_bib0027","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12916-018-1017-7","article-title":"Adaptive designs in clinical trials: why use them, and how to run and report them","volume":"16","author":"Pallmann","year":"2018","journal-title":"BMC Med"},{"key":"10.1016\/j.ahj.2024.01.004_bib0028","unstructured":"FDA: new drug development and review Process https:\/\/www.fda.gov\/drugs\/cder-small-business-industry-assistance-sbia\/new-drug-development-and-review-process (accessed 16 December, 2022)."},{"key":"10.1016\/j.ahj.2024.01.004_bib0029","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1158\/1078-0432.CCR-20-3868","article-title":"Modernizing clinical trial eligibility criteria: recommendations of the ASCO-friends of Cancer Research Performance Status Work Group","volume":"27","author":"Magnuson","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ahj.2024.01.004_bib0030","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1200\/JCO.2012.43.6931","article-title":"Making genuine progress against metastatic breast cancer","volume":"30","author":"Lyman","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ahj.2024.01.004_bib0031","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12874-020-00926-y","article-title":"A novel approach to conducting clinical trials in the community setting: utilizing patient-driven platforms and social media to drive web-based patient recruitment","volume":"20","author":"Applequist","year":"2020","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.ahj.2024.01.004_bib0032","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/s41591-020-1089-8","article-title":"Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial","volume":"26","author":"Burd","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.ahj.2024.01.004_bib0033","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1377\/hlthaff.2017.1553","article-title":"Specialty drug coverage varies across commercial health plans in the US","volume":"37","author":"Chambers","year":"2018","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.ahj.2024.01.004_bib0034","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1007\/s40265-020-01427-4","article-title":"Pralsetinib: first approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.ahj.2024.01.004_bib0035","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/CIRCULATIONAHA.115.020406","article-title":"Shared risk factors in cardiovascular disease and cancer","volume":"133","author":"Koene","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2024.01.004_bib0036","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/1471-2407-10-105","article-title":"Long-term survival of cancer patients compared to heart failure and stroke: a systematic review","volume":"10","author":"Askoxylakis","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ahj.2024.01.004_bib0037","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s10865-017-9860-0","article-title":"Heart disease versus cancer: understanding perceptions of population prevalence and personal risk","volume":"40","author":"Scheideler","year":"2017","journal-title":"J Behav Med"},{"key":"10.1016\/j.ahj.2024.01.004_bib0038","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/pubmed\/fdn009","article-title":"Misrepresentation of health risks by mass media","volume":"30","author":"Bomlitz","year":"2008","journal-title":"J Public Health (Oxf)"},{"key":"10.1016\/j.ahj.2024.01.004_bib0039","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1742-1241.2011.02658.x","article-title":"Death and illness as depicted in the media","volume":"65","author":"Williamson","year":"2011","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.ahj.2024.01.004_bib0040","unstructured":"Owenshen24: death: reality vs reported (https:\/\/owenshen24.github.io\/charting-death\/- accessed 26 December, 2023)."},{"key":"10.1016\/j.ahj.2024.01.004_bib0041","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3389\/fpubh.2020.00279","article-title":"Actual causes of death in relation to media, policy, and funding attention: examining public health priorities","volume":"8","author":"Pilar","year":"2020","journal-title":"Front Public Health"},{"key":"10.1016\/j.ahj.2024.01.004_bib0042","unstructured":"Causes of death in the US: what Americans die from, what they search on Google, and what the media reports on (https:\/\/en.m.wikipedia.org\/wiki\/File:Causes-of-death-in-USA-vs.-media-coverage.png accessed 26 December, 2023)."},{"key":"10.1016\/j.ahj.2024.01.004_bib0043","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/j.ijcard.2013.12.095","article-title":"Alignment of United States funding for cardiovascular disease research with deaths, years of life lost, and hospitalizations","volume":"172","author":"Stockmann","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ahj.2024.01.004_bib0044","doi-asserted-by":"crossref","first-page":"219","DOI":"10.15430\/JCP.2021.26.4.219","article-title":"The 50-year war on cancer revisited: should we continue to fight the enemy within?","volume":"26","author":"Surh","year":"2021","journal-title":"J Cancer Prev"},{"key":"10.1016\/j.ahj.2024.01.004_bib0045","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/eurheartj\/ehv641","article-title":"Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study","volume":"37","author":"Nielsen","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2024.01.004_bib0046","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011765","article-title":"Patient-reported reasons for declining or discontinuing statin therapy: insights from the PALM Registry","volume":"8","author":"Bradley","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ahj.2024.01.004_bib0047","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/453840a","article-title":"Translational research: crossing the valley of death","volume":"453","author":"Butler","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.ahj.2024.01.004_bib0048","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1001\/jama.2020.1166","article-title":"Estimated research and development investment needed to bring a new medicine to market, 2009-2018","volume":"323","author":"Wouters","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2024.01.004_bib0049","doi-asserted-by":"crossref","unstructured":"National Academies of Sciences, Engineering, and Medicine. 2021. Innovation in Drug Research and Development for Prevalent Chronic Diseases: Proceedings of a Workshop. Washington, DC: The National Academies Press. https:\/\/doi.org\/10.17226\/26291","DOI":"10.17226\/26291"},{"key":"10.1016\/j.ahj.2024.01.004_bib0050","doi-asserted-by":"crossref","first-page":"938","DOI":"10.7326\/M21-4442","article-title":"Medicare spending on drugs with accelerated approval","volume":"175","author":"Ballreich","year":"2022","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ahj.2024.01.004_bib0051","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S1470-2045(21)00709-9","article-title":"Global consequences of the US FDA's accelerated approval of cancer drugs","volume":"23","author":"Akhade","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ahj.2024.01.004_bib0052","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1001\/jamainternmed.2021.5989","article-title":"Estimated Medicare spending on cancer drug indications with a confirmed lack of clinical benefit after US Food and Drug Administration accelerated approval","volume":"181","author":"Shahzad","year":"2021","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ahj.2024.01.004_bib0053","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1186\/s13063-019-3664-1","article-title":"Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols","volume":"20","author":"Park","year":"2019","journal-title":"Trials"},{"key":"10.1016\/j.ahj.2024.01.004_bib0054","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.mayocp.2012.07.007","article-title":"The high cost of cancer drugs and what we can do about it","volume":"87","author":"Siddiqui","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ahj.2024.01.004_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100625","article-title":"Cost-effectiveness of cancer drugs: comparative analysis of the United States and England","volume":"29-30","author":"Cherla","year":"2020","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ahj.2024.01.004_bib0056","first-page":"1086","article-title":"Do value thresholds for oncology drugs differ from nononcology drugs?","volume":"20","author":"Bae","year":"2014","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.ahj.2024.01.004_bib0057","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1001\/jama.2016.2240","article-title":"Biomarkers and surrogate endpoints: developing common terminology and definitions","volume":"315","author":"Robb","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2024.01.004_bib0058","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41591-022-02160-z","article-title":"The next generation of evidence-based medicine","volume":"29","author":"Subbiah","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.ahj.2024.01.004_bib0059","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials","volume":"385","author":"Cholesterol Treatment Trialists","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2024.01.004_bib0060","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/j.jacc.2022.02.048","article-title":"High-intensity statin use among patients with atherosclerosis in the U.S","volume":"79","author":"Nelson","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2024.01.004_bib0061","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.48030","article-title":"Use of lipid-, blood pressure-, and glucose-lowering pharmacotherapy in patients with type 2 diabetes and atherosclerotic cardiovascular disease","volume":"5","author":"Nelson","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ahj.2024.01.004_bib0062","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.37765\/ajmc.2021.88673","article-title":"Heart failure population health considerations","volume":"27","author":"Patel","year":"2021","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.ahj.2024.01.004_bib0063","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.cardfail.2008.06.005","article-title":"The cost of medical management in advanced heart failure during the final two years of life","volume":"14","author":"Russo","year":"2008","journal-title":"J Card Fail"},{"key":"10.1016\/j.ahj.2024.01.004_bib0064","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2024.01.004_bib0065","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1093\/eurheartj\/ehac103","article-title":"Global disparities in prescription of guideline-recommended drugs for heart failure with reduced ejection fraction","volume":"43","author":"Tromp","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2024.01.004_bib0066","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/ejhf.1869","article-title":"Effects of combined renin-angiotensin-aldosterone system inhibitor and beta-blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from BIOSTAT-CHF and ASIAN-HF registries","volume":"22","author":"Ouwerkerk","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ahj.2024.01.004_bib0067","doi-asserted-by":"crossref","first-page":"e1008","DOI":"10.1016\/S2214-109X(18)30306-1","article-title":"Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study","volume":"6","author":"Teng","year":"2018","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.ahj.2024.01.004_bib0068","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry","volume":"72","author":"Greene","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2024.01.004_bib0069","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jchf.2018.10.010","article-title":"Contemporary drug treatment of chronic heart failure with reduced ejection fraction: the CHECK-HF registry","volume":"7","author":"Brunner-La Rocca","year":"2019","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.ahj.2024.01.004_bib0070","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1001\/jama.2023.4387","article-title":"It takes an average of 17 years for evidence to change practice-the burgeoning field of implementation science seeks to speed things up","volume":"329","author":"Rubin","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2024.01.004_bib0071","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"3 Engl J Med"},{"key":"10.1016\/j.ahj.2024.01.004_bib0072","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.01.004_bib0073","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.01.004_bib0074","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.01.004_bib0075","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.01.004_bib0076","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.019331","article-title":"Adoption of PCSK9 inhibitors among patients with atherosclerotic disease","volume":"10","author":"Dayoub","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ahj.2024.01.004_bib0077","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1002\/ehf2.12883","article-title":"Implementation of sacubitril\/valsartan in Sweden: clinical characteristics, titration patterns, and determinants","volume":"7","author":"Fu","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.ahj.2024.01.004_bib0078","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.cardfail.2021.05.015","article-title":"National trends in the use of sacubitril\/valsartan","volume":"27","author":"Ozaki","year":"2021","journal-title":"J Card Fail"},{"issue":"Suppl 1","key":"10.1016\/j.ahj.2024.01.004_bib0079","first-page":"S52","article-title":"Improving implementation of evidence-based therapies for heart failure","volume":"45","author":"DeVore","year":"2022","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.ahj.2024.01.004_bib0080","first-page":"e33509","article-title":"Underprescription of SGLT2i and GLP-1 RA: CAREPRO-T2D (cardiorenal protection in type 2 diabetes) cross-sectional study","volume":"15","author":"Simoes de Carvalho","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.ahj.2024.01.004_bib0081","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ahj.2017.09.004","article-title":"Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: an NCDR research to practice (R2P) project","volume":"195","author":"Hess","year":"2018","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2024.01.004_bib0082","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1093\/eurheartj\/ehaa034","article-title":"Application of the 2019 ESC\/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study","volume":"41","author":"Allahyari","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2024.01.004_bib0083","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2024.01.004_bib0084","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2024.01.004_bib0085","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2024.01.004_bib0086","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.121.008381","article-title":"Patterns of prescribing sodium-glucose cotransporter-2 inhibitors for Medicare beneficiaries in the United States","volume":"14","author":"Sangha","year":"2021","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.ahj.2024.01.004_bib0087","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.6139","article-title":"Association of race\/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US","volume":"4","author":"Eberly","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ahj.2024.01.004_bib0088","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1001\/jama.297.8.831","article-title":"Deficits in communication and information transfer between hospital-based and primary care physicians: implications for patient safety and continuity of care","volume":"297","author":"Kripalani","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2024.01.004_bib0089","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1001\/jama.2019.11982","article-title":"Effect of a hospital-initiated program combining transitional care and long-term self-management support on outcomes of patients hospitalized with chronic obstructive pulmonary disease: a randomized clinical trial","volume":"322","author":"Aboumatar","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2024.01.004_bib0090","first-page":"e122","volume":"135","author":"Chan","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2024.01.004_bib0091","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.ahj.2011.06.007","article-title":"Medication adherence: a call for action","volume":"162","author":"Bosworth","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2024.01.004_bib0092","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1377\/hlthaff.2014.0516","article-title":"The ethics of 'fail first': guidelines and practical scenarios for step therapy coverage policies","volume":"33","author":"Nayak","year":"2014","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.ahj.2024.01.004_bib0093","article-title":"The night of randomized clinical trials where all patients are black: a need to estimate variability in treatment effects","volume":"1","author":"de Gaetano","year":"2022","journal-title":"Bleed Thromb Vasc Biol"},{"key":"10.1016\/j.ahj.2024.01.004_bib0094","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.pcd.2017.01.007","article-title":"Clinical inertia-time to reappraise the terminology?","volume":"11","author":"Khunti","year":"2017","journal-title":"Prim Care Diabetes"},{"key":"10.1016\/j.ahj.2024.01.004_bib0095","unstructured":"Henriksen K, Battles JB, Marks ES, et al., editors. Advances in Patient Safety: From Research to Implementation 4: Programs, Tools, and Products. Rockville (MD): Agency for Healthcare Research and Quality (US); 2005 Feb. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK20594\/"},{"key":"10.1016\/j.ahj.2024.01.004_bib0096","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.jacc.2019.02.015","article-title":"Titration of medical therapy for heart failure with reduced ejection fraction","volume":"73","author":"Greene","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2024.01.004_bib0097","doi-asserted-by":"crossref","first-page":"70","DOI":"10.7326\/M19-0476","article-title":"Austrian Working Group of Heart F. prescription bias in the treatment of chronic systolic heart failure","volume":"172","author":"Arfsten","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ahj.2024.01.004_bib0098","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2337\/cd19-0009","article-title":"Therapeutic inertia is a problem for all of us","volume":"37","author":"Brunton","year":"2019","journal-title":"Clin Diabetes"},{"key":"10.1016\/j.ahj.2024.01.004_bib0099","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.2337\/dc13-0331","article-title":"Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people","volume":"36","author":"Khunti","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ahj.2024.01.004_bib0100","first-page":"1507","article-title":"Polypharmacy and optimization of guideline-directed medical therapy in heart failure: the GUIDE-IT trial","volume":"1111","author":"Khan","year":"2023","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.ahj.2024.01.004_bib0101","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/ejhf.2283","article-title":"Clinical inertia and medical therapy for heart failure: the unintended harms of 'first, do no harm'","volume":"23","author":"Greene","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ahj.2024.01.004_bib0102","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jchf.2020.04.019","article-title":"Care gaps in adherence to heart failure guidelines: clinical inertia or physiological limitations?","volume":"8","author":"Jarjour","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.ahj.2024.01.004_bib0103","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jchf.2018.11.011","article-title":"Target doses of heart failure medical therapy and blood pressure: insights from the CHAMP-HF registry","volume":"7","author":"Peri-Okonny","year":"2019","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.ahj.2024.01.004_bib0104","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/ejhf.2252","article-title":"Treatment patterns and clinical outcomes among patients <65 years with a worsening heart failure event","volume":"23","author":"Butler","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ahj.2024.01.004_bib0105","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1002\/ejhf.2287","article-title":"Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care","volume":"23","author":"Trevisan","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ahj.2024.01.004_bib0106","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1002\/ejhf.2024","article-title":"Effects of hyperkalaemia and non-adherence to renin-angiotensin-aldosterone system inhibitor therapy in patients with heart failure in Italy: a propensity-matched study","volume":"22","author":"Volterrani","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ahj.2024.01.004_bib0107","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.ejheart.2008.08.001","article-title":"Cardiologists' awareness and perceptions of guidelines for chronic heart failure. The ADDress your heart survey","volume":"10","author":"Erhardt","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ahj.2024.01.004_bib0108","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1200\/JCO.2015.66.3658","article-title":"The effects of oncologist implicit racial bias in racially discordant oncology interactions","volume":"34","author":"Penner","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ahj.2024.01.004_bib0109","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1146\/annurev-pharmtox-010716-104952","article-title":"Changing provider behavior in the context of chronic disease management: focus on clinical inertia","volume":"57","author":"Lavoie","year":"2017","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.ahj.2024.01.004_bib0110","doi-asserted-by":"crossref","first-page":"825","DOI":"10.7326\/0003-4819-135-9-200111060-00012","article-title":"Clinical inertia","volume":"135","author":"Phillips","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ahj.2024.01.004_bib0111","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1111\/j.1742-1241.2007.01420.x","article-title":"A global survey of physicians' perceptions on cholesterol management: the from the heart study","volume":"61","author":"Erhardt","year":"2007","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.ahj.2024.01.004_bib0112","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2147\/PPA.S124192","article-title":"Herding: a new phenomenon affecting medical decision-making in multiple sclerosis care? Lessons learned from DIScUTIR MS","volume":"11","author":"Saposnik","year":"2017","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.ahj.2024.01.004_bib0113","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3389\/fneur.2017.00065","article-title":"Decision-making in multiple sclerosis: the role of aversion to ambiguity for therapeutic inertia among neurologists (DIScUTIR MS)","volume":"8","author":"Saposnik","year":"2017","journal-title":"Front Neurol"},{"key":"10.1016\/j.ahj.2024.01.004_bib0114","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.1016\/S2468-2667(20)30144-4","article-title":"Education: a neglected social determinant of health","volume":"5","year":"2020","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.ahj.2024.01.004_bib0115","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1001\/jamacardio.2019.4987","article-title":"Patient perceptions and familiarity with medical therapy for heart failure","volume":"5","author":"Samsky","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ahj.2024.01.004_bib0116","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1126\/science.aap9559","article-title":"The spread of true and false news online","volume":"359","author":"Vosoughi","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ahj.2024.01.004_bib0117","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11883-020-00853-9","article-title":"Statins in a distorted mirror of media","volume":"22","author":"Nelson","year":"2020","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.ahj.2024.01.004_bib0118","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-012613","article-title":"A content analysis of the representation of statins in the British newsprint media","volume":"7","author":"Chisnell","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.ahj.2024.01.004_bib0119","doi-asserted-by":"crossref","first-page":"i3283","DOI":"10.1136\/bmj.i3283","article-title":"Impact of statin related media coverage on use of statins: interrupted time series analysis with UK primary care data","volume":"353","author":"Matthews","year":"2016","journal-title":"BMJ"},{"issue":"Suppl 3","key":"10.1016\/j.ahj.2024.01.004_bib0120","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/1472-6947-13-S3-S5","article-title":"Media, messages, and medication: strategies to reconcile what patients hear, what they want, and what they need from medications","volume":"13","author":"Kravitz","year":"2013","journal-title":"BMC Med Inform Decis Mak"},{"key":"10.1016\/j.ahj.2024.01.004_bib0121","article-title":"Plain language summary and patient perspective of the American Society for Clinical Oncology guideline: management of stage 3 non-small-cell lung cancer","author":"Jenkins","year":"2023","journal-title":"Future Oncol"},{"key":"10.1016\/j.ahj.2024.01.004_bib0122","article-title":"Plain language summary and patient perspective of the 2020 lung cancer screening recommendations by the US Preventive Services Task Force","author":"Jenkins","year":"2023","journal-title":"Future Oncol"},{"key":"10.1016\/j.ahj.2024.01.004_bib0123","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1056\/NEJMp1209500","article-title":"Shared decision making to improve care and reduce costs","volume":"368","author":"Oshima Lee","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.01.004_bib0124","unstructured":"U.S. Food & Drug Administration: the drug development process https:\/\/www.fda.gov\/patients\/learn-about-drug-and-device-approvals\/drug-development-process (accessed 15 December, 2022)."},{"key":"10.1016\/j.ahj.2024.01.004_bib0125","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13012-020-01060-5","article-title":"Integrating implementation science in clinical research to maximize public health impact: a call for the reporting and alignment of implementation strategy use with implementation outcomes in clinical research","volume":"15","author":"Rudd","year":"2020","journal-title":"Implement Sci"},{"key":"10.1016\/j.ahj.2024.01.004_bib0126","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/intqhc\/mzaa127","article-title":"Innovating health care: key characteristics of human-centered design","volume":"33","author":"Melles","year":"2021","journal-title":"Int J Qual Health Care"},{"key":"10.1016\/j.ahj.2024.01.004_bib0127","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1001\/jamacardio.2023.2106","article-title":"Diversity in clinical trial enrollment and reporting-where we are and the road ahead","volume":"8","author":"Farb","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ahj.2024.01.004_bib0128","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jamacardio.2017.3606","article-title":"Incorporating patient and caregiver experiences into cardiovascular clinical trial design","volume":"2","author":"Collins","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ahj.2024.01.004_bib0129","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2022.4631","article-title":"Value-based pricing of US prescription drugs: estimated savings using reports from the institute for clinical and economic review","volume":"3","author":"Yeung","year":"2022","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.ahj.2024.01.004_bib0130","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1161\/CIRCULATIONAHA.120.052339","article-title":"Sex, permanent drug discontinuation, and study retention in clinical trials: insights from the TIMI trials","volume":"143","author":"Lau","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2024.01.004_bib0131","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/bcp.14240","article-title":"How the EMERGE guideline on medication adherence can improve the quality of clinical trials","volume":"86","author":"Eliasson","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ahj.2024.01.004_bib0132","doi-asserted-by":"crossref","first-page":"e26003","DOI":"10.1002\/jia2.26003","article-title":"Perspectives of healthcare providers on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings from a Hybrid III Implementation-effectiveness study (CUSTOMIZE)","volume":"25","author":"Czarnogorski","year":"2022","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.ahj.2024.01.004_bib0133","doi-asserted-by":"crossref","first-page":"e26006","DOI":"10.1002\/jia2.26006","article-title":"Perspectives of people living with HIV-1 on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation-effectiveness study","volume":"25","author":"Garris","year":"2022","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.ahj.2024.01.004_bib0134","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa1909512","article-title":"Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection","volume":"382","author":"Orkin","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.01.004_bib0135","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","article-title":"Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression","volume":"382","author":"Swindells","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.01.004_bib0136","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s11606-020-06220-3","article-title":"Using implementation science-guided pilot studies to assess and improve the informativeness of clinical trials","volume":"36","author":"Taylor","year":"2021","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.ahj.2024.01.004_bib0137","unstructured":"FDA: treatment for heart failure: endpoints for drug development guidance for industry (https:\/\/www.fda.gov\/media\/128372\/download accessed 29 March, 2023)."},{"key":"10.1016\/j.ahj.2024.01.004_bib0138","unstructured":"FDA: Accelerated Approval (https:\/\/www.fda.gov\/patients\/fast-track-breakthrough-therapy-accelerated-approval-priority-review\/accelerated-approval accessed 15 April, 2023)."},{"key":"10.1016\/j.ahj.2024.01.004_bib0139","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1056\/NEJMp2208954","article-title":"The on- and off-ramps of oncology accelerated approval","volume":"387","author":"Fashoyin-Aje","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.01.004_bib0140","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1001\/jama.2023.0625","article-title":"Association between preapproval confirmatory trial initiation and conversion to traditional approval or withdrawal in the FDA accelerated approval pathway","volume":"329","author":"Shahzad","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2024.01.004_bib0141","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1001\/jamaoncol.2015.6477","article-title":"Evaluation and regulation of oncology drug approval: finding the right balance","volume":"2","author":"Lyman","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ahj.2024.01.004_bib0142","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ejca.2017.08.028","article-title":"Mind the gap' between the development of therapeutic innovations and the clinical practice in oncology: a proposal of the European Organisation for Research and Treatment of Cancer (EORTC) to optimise cancer clinical research","volume":"86","author":"Kempf","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ahj.2024.01.004_bib0143","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1001\/jamainternmed.2015.5868","article-title":"Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of US Food and Drug Administration approvals","volume":"175","author":"Kim","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ahj.2024.01.004_bib0144","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1001\/jamainternmed.2019.0462","article-title":"Assessment of the clinical benefit of cancer drugs receiving accelerated approval","volume":"179","author":"Gyawali","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ahj.2024.01.004_bib0145","doi-asserted-by":"crossref","first-page":"n1959","DOI":"10.1136\/bmj.n1959","article-title":"Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study","volume":"374","author":"Gyawali","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ahj.2024.01.004_bib0146","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S1470-2045(23)00020-7","article-title":"Modernising the US FDA's accelerated approval pathway","volume":"24","author":"Benjamin","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ahj.2024.01.004_bib0147","unstructured":"Federal Register: Clinical trial considerations to support accelerated approval of oncology therapeutics; draft guidance for industry (https:\/\/www.federalregister.gov\/documents\/2023\/03\/27\/2023-05910\/clinical-trial-considerations-to-support-accelerated-approval-of-oncology-therapeutics-draft accessed 16 April, 2023."},{"key":"10.1016\/j.ahj.2024.01.004_bib0148","unstructured":"FDA table of surrogate endpoints that were the basis of drug approval or licensure (https:\/\/www.fda.gov\/drugs\/development-resources\/table-surrogate-endpoints-were-basis-drug-approval-or-licensure accessed 16 April, 2023."},{"key":"10.1016\/j.ahj.2024.01.004_bib0149","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1161\/CIRCULATIONAHA.119.041022","article-title":"Impact of regulatory guidance on evaluating cardiovascular risk of new glucose-lowering therapies to treat type 2 diabetes mellitus: lessons learned and future directions","volume":"141","author":"Sharma","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2024.01.004_bib0150","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s43441-020-00175-7","article-title":"Designing, conducting, monitoring, and analyzing data from pragmatic randomized clinical trials: proceedings from a multi-stakeholder think tank meeting","volume":"54","author":"Lentz","year":"2020","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.ahj.2024.01.004_bib0151","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2022.106816","article-title":"Preface to theme issue on pragmatic and virtual trials: progress and challenges","volume":"119","author":"Hernandez","year":"2022","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.ahj.2024.01.004_bib0152","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/nrcardio.2015.33","article-title":"Registry-based randomized clinical trials: a new clinical trial paradigm","volume":"12","author":"James","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.ahj.2024.01.004_bib0153","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1056\/NEJMp1310102","article-title":"The randomized registry trial: the next disruptive technology in clinical research?","volume":"369","author":"Lauer","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.01.004_bib0154","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1056\/NEJMoa1308789","article-title":"Thrombus aspiration during ST-segment elevation myocardial infarction","volume":"369","author":"Frobert","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.01.004_bib0155","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa1706443","article-title":"Bivalirudin versus heparin monotherapy in myocardial infarction","volume":"377","author":"Erlinge","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.01.004_bib0156","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMra1510059","article-title":"Pragmatic trials","volume":"375","author":"Ford","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.01.004_bib0157","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/ejhf.2480","article-title":"Clinical trials: conventional or pragmatic?","volume":"24","author":"Tavazzi","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ahj.2024.01.004_bib0158","unstructured":"FDA framework for FDA's real-world evidence program (https:\/\/www.fda.gov\/media\/120060\/download accessed 3 September, 2023."},{"key":"10.1016\/j.ahj.2024.01.004_bib0159","unstructured":"FDA international regulatory harmonization https:\/\/www.fda.gov\/drugs\/cder-international-program\/international-regulatory-harmonization (accessed 16 December, 2022)."},{"key":"10.1016\/j.ahj.2024.01.004_bib0160","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1200\/JOP.19.00606","article-title":"Impact of pharmacy benefit managers on oncology practices and patients","volume":"16","author":"Royce","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.ahj.2024.01.004_bib0161","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s40273-017-0489-1","article-title":"Pharmacy benefit management companies: do they create value in the US healthcare system?","volume":"35","author":"Lyles","year":"2017","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.ahj.2024.01.004_bib0162","unstructured":"Fierce Healthcare: FDA's Robert Califf calls on insurers to help providers participate in critical clinical drug trials (https:\/\/www.fiercehealthcare.com\/payers\/fdas-califf-calls-insurers-help-providers-participate-critical-clinical-drug-trials (accessed 9 May, 2023)."},{"key":"10.1016\/j.ahj.2024.01.004_bib0163","unstructured":"CMS: Medicare coverage \u223c clinical trials: final national coverage decision (https:\/\/www.cms.gov\/medicare\/coverage\/clinicaltrialpolicies\/downloads\/finalnationalcoverage.pdf - accessed 03 September, 2023)."},{"key":"10.1016\/j.ahj.2024.01.004_bib0164","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1200\/EDBK_100003","article-title":"Value in oncology: balance between quality and cost","volume":"35","author":"Raghavan","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.ahj.2024.01.004_bib0165","unstructured":"Cigna reaches pay-for-performance deals for PCSK9 inhibitors https:\/\/www.ajmc.com\/view\/cigna-reaches-pay-for-performance-deals-for-pcsk9-inhibitors - accessed 16 December, 2022."},{"key":"10.1016\/j.ahj.2024.01.004_bib0166","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1001\/jama.2018.15782","article-title":"Alternative state-level financing for hepatitis C treatment-the \"Netflix model\"","volume":"320","author":"Trusheim","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2024.01.004_bib0167","unstructured":"National Institute on Minority Health and Health Disparities: diversity and inclusion in clinical trials (https:\/\/www.nimhd.nih.gov\/resources\/understanding-health-disparities\/diversity-and-inclusion-in-clinical-trials.html accessed 14 April, 2023)."},{"key":"10.1016\/j.ahj.2024.01.004_bib0168","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1056\/NEJMp2215609","article-title":"Why diverse clinical trial participation matters","volume":"388","author":"Schwartz","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.01.004_bib0169","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/ehjcvp\/pvac052","article-title":"RNA-targeted therapeutics in cardiovascular disease: the time is now","volume":"9","author":"Krychtiuk","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.ahj.2024.01.004_bib0170","unstructured":"TCTMD: pricey inclisiran is rolling out: a \u2018buy-and-bill\u2019 model may smooth its path (https:\/\/www.tctmd.com\/news\/pricey-inclisiran-rolling-out-buy-and-bill-model-may-smooth-its-path accessed 26 May, 2023)."},{"key":"10.1016\/j.ahj.2024.01.004_bib0171","unstructured":"Scrip: buy-and-bill a bust for novartis's leqvio? (https:\/\/scrip.pharmaintelligence.informa.com\/SC147413\/BuyAndBill-A-Bust-For-Novartiss-Leqvio?vid=Pharma - accessed 26 May, 2023)."},{"key":"10.1016\/j.ahj.2024.01.004_bib0172","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1302\/0301-620X.99B11.BJJ-2017-0647","article-title":"Population-based contracting (population health): part II","volume":"99-B","author":"Jacofsky","year":"2017","journal-title":"Bone Joint J"},{"key":"10.1016\/j.ahj.2024.01.004_bib0173","unstructured":"National Institute for Health and Care Excellence (NICE): Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia technology appraisal guidance [TA733] https:\/\/www.nice.org.uk\/guidance\/ta733 (accessed 16 December, 2022)."},{"key":"10.1016\/j.ahj.2024.01.004_bib0174","doi-asserted-by":"crossref","first-page":"n3025","DOI":"10.1136\/bmj.n3025","article-title":"GP leaders warn over the rollout of cholesterol lowering inclisiran in primary care","volume":"375","author":"Wise","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ahj.2024.01.004_bib0175","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1136\/bmj.p1757","article-title":"GP leaders advise practices not to prescribe cholesterol lowering drug inclisiran","volume":"382","author":"Iacobucci","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.ahj.2024.01.004_bib0176","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1001\/jama.2018.1150","article-title":"Health care spending in the United States and other high-income countries","volume":"319","author":"Papanicolas","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2024.01.004_bib0177","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1111\/liv.15245","article-title":"The payer license agreement, or \"Netflix model,\" for hepatitis C virus therapies enables universal treatment access, lowers costs and incentivizes innovation and competition","volume":"42","author":"Matthews","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.ahj.2024.01.004_bib0178","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2021.2291","article-title":"Medicaid subscription-based payment models and implications for access to hepatitis C medications","volume":"2","author":"Auty","year":"2021","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.ahj.2024.01.004_bib0179","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2016.11.004","volume":"69","author":"Chan","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2024.01.004_bib0180","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJMp1712984","article-title":"Nudge units to improve the delivery of health care","volume":"378","author":"Patel","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.01.004_bib0181","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1177\/1010539517743630","article-title":"Nobel prizes, nudge theory, and public health","volume":"29","author":"Binns","year":"2017","journal-title":"Asia Pac J Public Health"},{"key":"10.1016\/j.ahj.2024.01.004_bib0182","first-page":"40","article-title":"Effect of passive choice and active choice interventions in the electronic health record to cardiologists on statin prescribing: a cluster randomized clinical trial","volume":"6","author":"Adusumalli","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ahj.2024.01.004_bib0183","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1001\/jamacardio.2022.4373","article-title":"Effect of nudges to clinicians, patients, or both to increase statin prescribing: a cluster randomized clinical trial","volume":"8","author":"Adusumalli","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ahj.2024.01.004_bib0184","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1161\/CIRCULATIONAHA.120.051863","article-title":"An electronically delivered patient-activation tool for intensification of medications for chronic heart failure with reduced ejection fraction: the EPIC-HF trial","volume":"143","author":"Allen","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2024.01.004_bib0185","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.jacc.2023.02.005","article-title":"Cluster-randomized trial comparing ambulatory decision support tools to improve heart failure care","volume":"81","author":"Mukhopadhyay","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2024.01.004_bib0186","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1001\/jamacardio.2019.3066","article-title":"Effectiveness of interventions aimed at increasing statin-prescribing rates in primary cardiovascular disease prevention: a systematic review of randomized clinical trials","volume":"4","author":"Sparrow","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ahj.2024.01.004_bib0187","article-title":"Results of a remotely delivered hypertension and lipid program in more than 10 000 patients across a diverse health care network","volume":"8","author":"Blood","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ahj.2024.01.004_bib0188","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.ahj.2022.10.079","article-title":"Coordinating Cardiology clinics randomized trial of interventions to improve outcomes (COORDINATE) - diabetes: rationale and design","volume":"256","author":"Nelson","year":"2023","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2024.01.004_bib0189","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1001\/jama.2023.2854","article-title":"Coordinated care to optimize cardiovascular preventive therapies in type 2 diabetes: a randomized clinical trial","volume":"329","author":"Pagidipati","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2024.01.004_bib0190","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/eurjpc\/zwac204","article-title":"How to optimize the adherence to a guideline-directed medical therapy in the secondary prevention of cardiovascular diseases: a clinical consensus statement from the European Association of Preventive Cardiology","volume":"30","author":"Pedretti","year":"2023","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.ahj.2024.01.004_bib0191","unstructured":"Committee for quality assurance: healthcare effectiveness data and information set (HEDIS) (https:\/\/health.gov\/healthypeople\/objectives-and-data\/data-sources-and-methods\/data-sources\/healthcare-effectiveness-data-and-information-set-hedis- accessed 17 April, 2023."},{"key":"10.1016\/j.ahj.2024.01.004_bib0192","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/j.ahj.2004.09.015","article-title":"The American Heart Association get with the guidelines program","volume":"148","author":"Smaha","year":"2004","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2024.01.004_bib0193","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1001\/jamaneurol.2018.2101","article-title":"Participation in get with the guidelines-stroke and its association with quality of care for stroke","volume":"75","author":"Howard","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.ahj.2024.01.004_bib0194","doi-asserted-by":"crossref","first-page":"e233","DOI":"10.1161\/CIRCULATIONAHA.121.057125","article-title":"The American Heart Association's focus on primordial prevention","volume":"144","author":"Lloyd-Jones","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2024.01.004_bib0195","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1093\/eurheartj\/ehad459","article-title":"Will primordial prevention change cardiology?","volume":"44","author":"Braunwald","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2024.01.004_bib0196","first-page":"e596","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation."}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870324000139?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870324000139?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:11:44Z","timestamp":1757571104000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870324000139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":196,"alternative-id":["S0002870324000139"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2024.01.004","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug development for major chronic health conditions\u2014aligning with growing public health needs: Proceedings from a multistakeholder think tank","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2024.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}